Ranbaxy Laboratories has filed a complaint against the US Food and Drug Administration (USFDA) in D.C. federal court and has also asked the Court for a temporary restraining order to prevent any further action by USFDA until Ranbaxy’s case is decided. The pharma major has filed a complaint following, and in response to, the revocation of Ranbaxy’s tentative approvals for Ranbaxy’s ANDAs for esomeprazole magnesium delayed-release capsules and valganciclovir hydrochloride tablets.
Real Time News & Trading Trends Keep Liking Epic Research Private Limited
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co
No comments:
Post a Comment